Reveal Linq (cardiomonitor)

Reveal Linq represents the miniature implanted cardiomonitor which is developed to help doctors quickly and to precisely diagnose violations of a warm rhythm. The device is placed directly under skin through a small section less than 1 cm in an upper left part of a breast. The device is inserted by means of minimum invasive procedure that simplifies the procedure both for doctors, and for their patients.

2017: Approval of the American authorities

In March, 2017 the Medtronic company announced the beginning of sales of the cardiomonitor of new generation of Reveal Linq. High accuracy of work became its feature.

The Food and Drug Administration (FDA) issued Medtronic the certificate in form 510(k) for sale to the updated Reveal Linq model. The device received a programmable algorithm TruRhythm Detection thanks to which the device is capable to work with enhanced accuracy in comparison with predecessors. In particular, a system allows to reduce cases of false detection of bradycardia by 95% and for 47% to reduce the number of identifications of false delays in work of heart.

Reveal Linq cardiomonitor

According to the StarTribune edition in the publication of March 13, 2017, sale of kardimonitor of Linq generates Medtronic about $500 million annual revenue. In June, 2015 the producer said that this equipment will add the company to $1 billion income per year within five years.^[1]

Cardiomonitors help doctors to solve problems with violations of a warm rhythm, increasing quality of management of groups of patients. Improvements which are introduced by TruRhythm Detection are done by Reveal Linq more smart due to optimization of the studied data so that doctors could make decisions even quicker and more precisely — doctor James Allred working in Cone Health Medical Group HeartCare clinic said.

Notes